Loading…
Jupiter Neurosciences, Inc. is projected to rise to $0.1994 by 2027, a +5% move from its current price of $0.1899. JUNS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.1767 | $0.1902 | $0.2046 | +0.13% |
| Jul 13 | $0.1716 | $0.1904 | $0.2112 | +0.27% |
| Jul 14 | $0.1679 | $0.1907 | $0.2165 | +0.40% |
| Jul 15 | $0.1649 | $0.1909 | $0.2211 | +0.53% |
| Jul 16 | $0.1623 | $0.1912 | $0.2252 | +0.67% |
| Jul 17 | $0.1599 | $0.1914 | $0.2291 | +0.80% |
| Jul 18 | $0.1579 | $0.1917 | $0.2327 | +0.93% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.1579 | $0.1917 | $0.2327 | +0.93% |
| Week 2 | $0.147 | $0.1935 | $0.2546 | +1.88% |
| Week 3 | $0.1395 | $0.1953 | $0.2733 | +2.83% |
| Week 4 | $0.1337 | $0.1971 | $0.2906 | +3.79% |
| Week 5 | $0.1289 | $0.1989 | $0.307 | +4.76% |
| Week 6 | $0.1248 | $0.2008 | $0.323 | +5.74% |
| Week 7 | $0.1213 | $0.2027 | $0.3387 | +6.73% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company that develops therapeutics for central nervous system disorders and rare diseases in the United States and internationally.
It operates in two segments: Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name.
The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Jupiter Neurosciences, Inc. (JUNS) trades in the Healthcare sector. The current price is $0.1928 and the market capitalization is $9.3M. It is ranked 5135 in market capitalization.
The forecast for 2026 shows the min, avg, and max as $0.1928, $0.1928, and $0.2953 respectively, with an ROI of 0 and a sentiment labeled NEUTRAL. The 30-day range is $0.1155 to $0.3218, with a support at $0.193 and a resistance at $0.29.
Beyond 2026, the forecast indicates potential upside in later years with bullish periods such as 2032 (avg $0.2553, ROI 32.4) and 2033 (avg $0.2355, ROI 22.1), and stronger upside in 2040 (avg $0.2853, ROI 48) and 2050 (avg $0.6338, ROI 228.8). The 2050 max is $1.46. These figures reflect probabilistic outcomes and are not guarantees.
A major floor 35.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.1% away) — a key level to hold.
The nearest ceiling, 52.7% above — a clean break opens room to run.
A major ceiling 144.9% above — clearing it would confirm fresh momentum.
Key JUNS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of JUNS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.2032 | Sell | $0.2009 | Sell |
| MA 10 | $0.2158 | Sell | $0.211 | Sell |
| MA 20 | $0.2261 | Sell | $0.225 | Sell |
| MA 50 | $0.27 | Sell | $0.2752 | Sell |
| MA 100 | $0.3479 | Sell | $0.4035 | Sell |
| MA 200 | $0.7647 | Sell | $0.7498 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.39 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -153.62 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -19.49 | Sell |
| Bollinger %B (20,2) | 0.06 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.98 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 31.04 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 0.19 | Sell |
| ADX (14) | 18.58 | Neutral |
| ATR (14) | 0.01 | Info |
The 30-day technical picture shows bearish sentiment. RSI14 is 40. The price is trading below the SMA50 of $0.2769 and well below the SMA200 of $0.7765. A nearby support sits at $0.193 and a resistance at $0.29.
The 30-day range runs from $0.1155 to $0.3218, highlighting the short-term volatility. Annualized volatility is listed at 100.00, underscoring how swingy the price action has been. These factors suggest limited near-term upside with risk of further declines.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.1899 | $0.1899 | $0.2902 | 0% | Neutral | |
| $0.1446 | $0.1994 | $0.2971 | +5% | Neutral | |
| $0.1078 | $0.1579 | $0.2507 | -17% | Bearish | |
| $0.116 | $0.179 | $0.2984 | -6% | Neutral | |
| $0.0985 | $0.1594 | $0.2766 | -16% | Bearish | |
| $0.1078 | $0.1823 | $0.3276 | -4% | Neutral | |
| $0.142 | $0.2505 | $0.464 | +32% | Bullish | |
| $0.1267 | $0.2326 | $0.4429 | +23% | Bullish | |
| $0.1157 | $0.221 | $0.4315 | +16% | Neutral | |
| $0.1031 | $0.2048 | $0.4092 | +8% | Neutral | |
| $0.1261 | $0.2802 | $0.615 | +48% | Bullish | |
| $0.2809 | $0.6242 | $1.44 | +229% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.1899 | $0.1899 | $0.2303 | +0.00% |
| August 2026 | $0.1659 | $0.2011 | $0.2539 | +5.89% |
| September 2026 | $0.1744 | $0.2144 | $0.2762 | +6.60% |
| October 2026 | $0.1687 | $0.2099 | $0.2752 | -2.07% |
| November 2026 | $0.1649 | $0.2073 | $0.2757 | -1.26% |
| December 2026 | $0.1697 | $0.2154 | $0.2902 | +3.90% |
Click any year to see its month-by-month JUNS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, JUNS could reach as high as $0.2902, with a base case around $0.1899 and support toward $0.1899 — roughly 0% from $0.1899. A consolidation phase looks the most probable path here.
Expect JUNS to range from $0.1446 to $0.2971 through 2027. The $0.1994 average target implies a +5% move from current prices. That is up +5% on the projected 2026 average. Price action looks broadly range-bound.
The JUNS price prediction for 2028 points to an average of $0.1579 (low $0.1078, high $0.2507) — a potential decline of -17% on today's $0.1899. Expect choppier, lower action through this leg of the cycle.
In 2029, JUNS is projected to trade between $0.116 and $0.2984, averaging $0.179 — a potential decline of -6% from today's $0.1899. That is up +13% on the projected 2028 average. Price action looks broadly range-bound.
Jupiter Neurosciences, Inc.'s 2030 outlook centres on $0.1594, within a $0.0985 to $0.2766 range. That is -11% versus the projected 2029 average. That marks a -16% change versus current levels. Expect choppier, lower action through this leg of the cycle.
By 2031, JUNS could reach as high as $0.3276, with a base case around $0.1823 and support toward $0.1078 — roughly -4% from $0.1899. Price action looks broadly range-bound.
Expect JUNS to range from $0.142 to $0.464 through 2032. The $0.2505 average target implies a +32% move from current prices. That is up +37% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The JUNS price prediction for 2033 points to an average of $0.2326 (low $0.1267, high $0.4429) — a potential gain of +23% on today's $0.1899. Momentum favours further upside here.
In 2034, JUNS is projected to trade between $0.1157 and $0.4315, averaging $0.221 — a potential gain of +16% from today's $0.1899. That is -5% versus the projected 2033 average. A consolidation phase looks the most probable path here.
Jupiter Neurosciences, Inc.'s 2035 outlook centres on $0.2048, within a $0.1031 to $0.4092 range. That is -7% versus the projected 2034 average. That marks a +8% change versus current levels. Price action looks broadly range-bound.
By 2040, JUNS could reach as high as $0.615, with a base case around $0.2802 and support toward $0.1261 — roughly +48% from $0.1899. Buyers look set to stay in control over this stretch.
Expect JUNS to range from $0.2809 to $1.44 through 2050. The $0.6242 average target implies a +229% move from current prices. That is up +123% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in JUNS today (≈ 5,265.929437 JUNS) could be worth
$3,287.11
+$2,287.11 (+229%) by 2050 · US Dollar
Based on the average projected JUNS price of $0.62 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in JUNSwould be worth at today's price.
$1,000 invested in JUNS on Jul 10, 2025 (≈ 523.560219 JUNS) would be worth
$99.42
-$900.58 (-90.1%) today · 0.10× · US Dollar
Based on a JUNS entry price of $1.91 vs. today's $0.1899.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.223 | $851.57 | -14.8% |
| 1 month ago | $0.225 | $844 | -15.6% |
| 3 months ago | $0.399 | $475.94 | -52.4% |
| 6 months ago | $1.04 | $182.6 | -81.7% |
| 1 year ago | $1.91 | $99.42 | -90.1% |
| All time (1.6y) ago | $5.49 | $34.59 | -96.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our JUNS forecast.
Our base-case forecast reaches $0.38 around 2050.
Implied market cap at $0.38: $18.33M
Over the multi-year horizon, the forecast shows a mixed path with some years bearish and others bullish. In 2028 the avg is $0.1605 with ROI -16.8 and sentiment BEARISH; in 2030 the avg is $0.1611 with ROI -16.5 and sentiment BEARISH.
The forecast turns more positive in 2032 (avg $0.2553, ROI 32.4) and 2033 (avg $0.2355, ROI 22.1), with both years deemed BULLISH.
Further out, 2040 shows an avg of $0.2853 with ROI 48 and is BULLISH, while 2050 projects an avg of $0.6338 with ROI 228.8 and is BULLISH. The implied max price by 2050 is $1.46. These figures illustrate a wide range of potential outcomes and are not guarantees; they reflect probabilistic forecasts guided by the data provided.
Tap a question to reveal the answer.
Avg price $0.1611; ROI -16.5%; sentiment BEARISH. Note: Forecasts are not guarantees.
For 2026, min $0.1928, avg $0.1928, max $0.2953; ROI 0; sentiment NEUTRAL.
Yes. The 2050 forecast shows avg $0.6338, max $1.46, ROI 228.8, sentiment BULLISH.
Support $0.193; Resistance $0.29.
Avg price $0.2853; ROI 48; sentiment BULLISH.
Jupiter Neurosciences, Inc. Community Discussion
0Share your Jupiter Neurosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.